Quantitative Proteomics with siRNA Screening Identifies Novel Mechanisms of Trastuzumab Resistance in HER2 Amplified Breast Cancers
Alaina Boyer(Washington University in St. Louis), Ron Bose(Washington University in St. Louis)
Cited by 47
Related Papers
Breast Cancer Mutations <i>HER2V777L</i> and <i>PIK3CAH1047R</i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
|Cancer Research|2023|31
Analysis of somatic mutations across the kinome reveals loss-of-function mutations in multiple cancer types
|Scientific Reports|2017|14
Breast cancer mutations HER2 <sup>V777L</sup> and PIK3CA <sup>H1047R</sup> activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance
|bioRxiv (Cold Spring Harbor Laboratory)|2022|0
Cerebellum metastasis model of HER2-positive breast cancer unveils key role of IL34-induced Arg1+ macrophages
|bioRxiv (Cold Spring Harbor Laboratory)|2025|0